SPRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spruce Biosciences, Inc (SPRB) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of recent news catalysts, and neutral trading sentiment from insiders and hedge funds do not support a compelling investment case. Additionally, the technical indicators and options data do not signal a strong entry point. While analysts remain optimistic about the firm's therapy pipeline, the financials and lack of immediate catalysts suggest holding off on investment for now.
The MACD is positive at 0.507, indicating a bullish trend, but it is contracting. RSI at 57.841 is neutral, suggesting no clear overbought or oversold condition. Moving averages are converging, indicating indecision in price movement. Key resistance levels are at 70.608 and 73.819, while support levels are at 60.214 and 57.003.
Analysts remain optimistic about the potential of Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B, with price targets still significantly above the current price.
No recent news or congress trading data is available to act as a catalyst. Insider and hedge fund trading sentiment is neutral.
In Q4 2025, the company reported a 100% YoY drop in revenue, net income declined by 37.83% YoY to -$14,646,000, and EPS fell by 73.51% YoY to -11.28. Gross margin dropped to 0, reflecting a challenging financial situation.
Analysts have lowered price targets recently but maintain an Outperform or Buy rating. Citizens lowered the price target to $170 from $180, and H.C. Wainwright reduced it to $200 from $220, citing delays in therapy filing timelines.
